Company Overview and News

48
Aytu BioScience Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

2018-10-10 accesswire
ENGLEWOOD, CO / ACCESSWIRE / October 10, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the closing of an underwritten public offering on October 9, 2018, with total gross proceeds of $15.2 million which includes the full exercise of the underwriters' over-allotment option to purchase additional shares and warrants, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.
LTS-A AYTUZ AYTU LTS

49
Aytu BioScience Announces Pricing of $13.2 Million Underwritten Public Offering

2018-10-05 accesswire - 1
ENGLEWOOD, CO / ACCESSWIRE / October 5, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the pricing of an underwritten public offering with expected total gross proceeds of $13.2 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.
LTS-A AYTUZ AYTU LTS

 
OFS credit prices IPO at $20 a share to raise $50 million

2018-10-05 marketwatch
OFS Credit Co. Inc. OCCI, +0.00% priced its initial public offering at $20 a share on Friday, selling 2.5 million shares to raise $50 million. Shares of the close=end management investment company will start trading later Friday on the Nasdaq under the ticker symbol "OCCI". Ladenburg Thalmann & Co. Inc., a unit of Ladenburg Thalmann Financial Services Inc.m B. Riley FBR and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc.
LTS-A NHLD LTS

2
Ladenburg - If You Have To Play

2018-09-13 seekingalpha - 1
Ladenburg's (non-executive) Chairman - and 35% direct owner - is being accused of a pump and dump scheme.
LTS-A VGR LTS

 
Monroe Capital Corporation Announces Closing of Public Offering of $69 Million 5.75% Notes Due 2023

2018-09-12 globenewswire
CHICAGO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Monroe Capital Corporation (the “Company”) (NASDAQ: MRCC) announced today that it has closed an underwritten public offering of $69.0 million in aggregate principal amount of its 5.75% Notes due 2023 (including $9.0 million in aggregate principal amount of its 5.75% Notes due 2023 sold pursuant to the exercise in full by the underwriters of their over-allotment option) (the “Notes”), which resulted in net proceeds to the Company of approximately $66.
LTS-A NHLD MRCC LTS

 
Buy This Baby Bond, Yield 7.84% To Maturity - Risk Lower Than It Appears

2018-09-12 seekingalpha
Ladenburg Thalmann has 3 baby bonds ($25 par bonds) that trade on the NYSE. We will discuss the terms of these bonds.
LTS-A DTK MS LTS

1
Monroe Capital Corporation Prices Public Offering of $60 Million 5.75% Notes Due 2023

2018-09-06 globenewswire - 1
CHICAGO, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Monroe Capital Corporation (the “Company”) (NASDAQ: MRCC) announced today that it has priced an underwritten public offering of $60.0 million in aggregate principal amount of its 5.75% notes due 2023 (the “Notes”) which will result in net proceeds to the Company of approximately $57.7 million (or approximately $66.4 million if the underwriters fully exercise the overallotment option described below) based on a public offering price of 100% of the aggregate principal amount of the Notes, after deducting payment of underwriting discounts and commissions and estimated offering expenses payable by the Company.
LTS-A MRCC LTS

 
Monroe Capital Corporation Announces Public Offering of Notes and A- Rating from Egan-Jones Ratings Company

2018-09-05 globenewswire
CHICAGO, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Monroe Capital Corporation (the “Company”) (NASDAQ: MRCC) announced today that it has commenced an underwritten public offering of unsecured notes due 2023 (the “Notes”), subject to market and other conditions. The Company also announced that it has received a rating of “A-” from Egan-Jones Ratings Company, an independent, unaffiliated rating agency.
LTS-A MRCC LTS

2
New Preferred Stock IPOs, August 2018

2018-09-04 seekingalpha - 1
Seven new preferred stocks were introduced during August, offering an average annual dividend of 6.6 percent.
SAB GAIN GAINM OAK PSA.A PRU GADDP USB CAI PSAXZ LTS-A PRU PFK CAIIP LTS PSA SAR SAQ PRH PJH

1
Ladenburg Thalmann Financial Services: This 7.25% Baby Bond Has Begun Trading On The AMEX

2018-08-26 seekingalpha - 1
Comparison with all other baby bonds that pay a fixed rate and have a maturity date of between 5 to 15 years.
LTS-A LTSK DTK LTS

1
Gladstone Investment Corporation Announces Closing of Offering of 2,990,000 Shares of its 6.375% Series E Cumulative Term Preferred Stock for Gross Proceeds of Approximately $74.8 million

2018-08-22 globenewswire
MCLEAN, Va., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Gladstone Investment Corporation (Nasdaq: GAIN) (the “Company”) today announced that it closed its previously announced offering of 2,600,000 shares of its newly-designated 6.375% Series E Cumulative Term Preferred Stock due 2025 (the “Series E Term Preferred Shares”) at a public offering price of $25.00 per share. Simultaneously with the closing of the offering, the underwriters exercised in full their option to purchase an additional 390,000 Series E Term Preferred Shares on the same terms to cover over-allotments, resulting in a total issuance of 2,990,000 shares for gross proceeds of approximately $74.
LTS-A NHLD GAIN GAINM LTS GADDP

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 50575Q201